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Abstract
Antibiotic resistance is an increasing problem across the world. The number of infections caused
by multidrug resistant bacteria is constantly increasing and the need for new antibiotics is very
urgent. Pseudomonas aeruginosa is a bacteria that has been listed as one of the most critical
bacteria that urgently need new antibiotics against due to the broad spectrum of infections it
can cause and its resistance against available antibiotics. Type 3 pantothenate kinase (PanK)
from P. aeruginosa was chosen as the target for the discovery of starting points for new antibi-
otics. Protocols for expression and purification of PanK were established. Crystals of PanK
were successfully formed but no data could be collected from them. Virtual screening identified
compounds that could potentially bind to the pantothenate binding site of PanK. A total amount
of 20 compounds were selected as potential inhibitors for PanK.
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Chapter 1
Introduction
1.1 Need for new antibiotics
Antibiotic resistance has been identified as a serious threat to human health and is a rising
problem all over the world. The emergence and spreading of new resistance mechanisms are
threatening our ability to treat common infections. The frequent use of antibiotics in hospitals,
community and agriculture have contributed to the development of resistance. In addition to the
cost of human lives, antibiotic resistance has caused countries with high income to use more ex-
pensive antibiotics which has caused high economic costs for health care. Furthermore, medical
interventions such as surgery, transplantation and chemotheraphy can also be hindered due to
antibiotic resistant bacteria [1].
1.2 Pseudomonas aeruginosa
Pseudomonas aeruginosa is a rod-shaped, gram-negative bacterium commonly found in soil,
water plants and animals. The bacteria species causes a variety of difficult to treat infections.
Infections from P. aeruginosa can be acquired from a stay in a healthcare facility such as hos-
pital or from the community. Patients with burns or cystic fibrosis are particularly susceptible
to nosocomial infections. Infections caused by these bacteria are associated with the biofilms
that this bacteria forms on the ventilators. Growing as a complex mass of cells attached to a
surface greatly increases the survival of P. aeruginosa since the resistant to biocides increases
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when compared to growing in a free-floating state [2] [3].
Antimicrobial therapy is becoming more problematic due to the resistance mechanism the
bacteria have. There are a number of factors that contribute to the resistance. The cell wall
of P. aeruginosa has low permeability which provides protection against antimicrobial agents.
The genome of P. aeruginosa is able to express a wide range of resistance factors and mutations
in chromosomal genes which regulate resistance genes can also contribute to resistance. Addi-
tionally, other organisms can provide additional resistance genes through plasmids, transposons
and bacteriophages [4]. Frequent use of antibiotics in setting where patiens are vulnerable to
P. aeruginosa infection has contributed to the development of resistance [2]. The emergence of
carbapenemases in multidrug resistant (MDR) strains of the bacteria has been very concerning
in recent years. This is due to the fact that now the MDR strains of the bacteria have become re-
sistant to carbapenems, which were used for the treatment of infections caused by MDR strains.
Moreover, colistin resistance in carbepenem resistant P. aeruginosa has been observed, where
colistin is an antibiotic used when there is no optiion left [2].
Furthermore, P. aeruginosa has several other mechanisms of resistance. One of the mech-
anisms involves the outer membrane that restricts the rate of penetration of small hydrophilic
molecules and excluding larger molecules. -lactams are small hydrophilic antibiotics that can
only cross the outer membrane by passing through the aqueous channels provided by porin pro-
teins. A specialized porin called oprD, is responsible for the uptake of positively charged amino
acids and loss of this porin is associated with resistance to the antibiotic imipenem. This is be-
cause oprD is required for imipenem to cross the outer membrane [4]. The permeability of the
outer membrane itself is already very restricted. The permeability is 12- to 100-fold lower than
that of E. coli and consists of a bilayer of phospholipid and lipopolysaccharide (LPS) , embed-
ded with protein channels [5]. LPS are a target of a group of antibiotics called aminoglycosides.
Aminoglycosides work by binding to LPS in order to increase the permeability of the membrane.
This will promote the uptake of antibiotics and once they are inside of the cell, protein synthe-
sis will be interfered. Although rarely observed, resistance against these aminoglycosides has
been observed in P. aeruginosa [4]. Due to the fact that P. aeruginosa has become resistant to a
large number of antibiotics and its ability to cause deadly infections, Word Health Organization
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(WHO) has included the species as amongst the most critical group of bacteria for which new
antibiotics are urgently needed for research and developing new antibiotics(Table 1.1).
Table 1.1: The priority list of pathogens for research and development of new antibiotic from WHO
Priority category Pathogens Antibiotic resistance
1: Critical Acinetobacter baumannii Carbapenem-resistant
1: Critical Pseudomonas aeruginosa Carbapenem-resistant
1: Critical Enterobacteriaceae Carbapenem-resistant, Extended spectrum beta-lactamases (ESBL) producing
2: High Enterococcus faecium vancomycin-resistant
2: High Staphylococcus aureus methicillin-resistant, vancomycin-intermediate and resistant
2: High Helicobacter pylori clarithromycin-resistant
2: High Campylobacter fluoroquinolone-resistant
2: High Salmonellae fluoroquinolone-resistant
2: High Neisseria gonorrhoeae cephalosporin-resistant and fluoroquinolone-resistant
3: Medium Streptococcus pneumoniae penicillin-non-susceptible
3: Medium Haemophilus influenzae ampicillin-resistant
3: Medium Shigella fluoroquinolone-resistant
1.3 Biosynthesis of CoA
Coenzyme A (CoA) is an important cofactor in the Krebs cycle and fatty acid metabolism and
is essential for all living organisms [6]. The biosynthesis of CoA (Figure 1.1) is a five step pro-
cess where the enzyme pantothenate kinase (PanK) is responsibe for the first step which will be
highlighted in the next section. Phosphopantothenoylcysteine synthetase (PPCS) is the enzyme
responsible for the second step in CoA biosynthesis. In this step, PPCS catalyzes the Mg2+-
dependent formation of 4’-phosphopantothenoylcysteine (PPC) by using the product from the
previous step, 4’-phosphopantothenate (PPan) , and L-cysteine. This step differs between eu-
karyotes and bacteria. In bacteria, cytidine triphosphate (CTP) is used for the activation of the
reaction whereas ATP (Adenosine Triphosphate) is used in eukaryotes. This difference has also
made PPCS an attractive target for the development of antimicrobial drugs. The enzyme re-
sponsible for the third step is called phosphopantothenoylcysteine decarboxylase (PPCDC) . In
bacteria, PPCS is fused to PPCDC and together they form a bifunctional CoaBC protein. The
eukaryotic counterpart of the enzymes does not have this function. The reaction that PPCDC
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catalyses is the decarboxylation of the cysteine moiety from PPC which gives the product 4’-
phosphopantetheine (PPantSH) [7]. In the fourth step, PPantSH undergoes an adenylylation to
form dephospho-CoA (dPCoA) and pyrophosphate. Just like the second step, this reaction is
dependent on Mg2+. The enzyme responsible for this reaction is phosphopantetheine adenylyl-
transferase (PPAT) . The eukaryotic version of PPAT is normally fused with dephospho-CoA
kinase (DPCK) which is the last enzyme of this pathway. This fusion protein is called CoA
synthase and does not exists in bacteria. DPCK catalyzes the phosphorylation of the 3’hydroxy-
group of the ribose moiety of dPCoAwhich results in ultimately CoA. This reaction is dependent
on MgATP. All enzymes in this pathway except DPCK are considered to be an attractive target
for drug development. Bacterial DPCK has high structural and sequence homology to the DPCK
domain of eukaryotic CoASy protein, suggesting that developing a selective inhibitor for bacte-
rial DPCK is unlikely [7].
Figure 1.1: The biosynthesis of CoA. Figure is taken from [8] (edited).
1.4 Pantothenate kinase
PanK is an enzyme that catalyzes the ATP-dependent phosphorylation of pantothenate to PPan
(Figure 1.2) and is considered as a potential target for the development of new antibiotic. This
1st step of the CoA biosynthesis pathway has been seen as a potential target for antimicrobial
drug development for several reasons [7]. This step is believed to be the rate-limiting step of the
pathway. Furthermore, there are three different types of PanKs all of which are diverse in terms
of sequence, structural fold and properties in catalysis and inhibition. All these factors suggest
that developing an inhibitor that selectively binds to the PanK of the pathogenic microorganism
of interest is possible [7].
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As mentioned in the previous paragraph, there are three different types of PanK. Type 1 Pank
is typically found in bacterial species such as Escherichia coli andMycobacterium tubercolosis,
and is encoded by the coaA gene. Type 1 PanK is regulated through feedback inhibition by CoA
and its thioesters [9].
Figure 1.2: The reaction that PanK catalyzes. The phosphoryl group from ATP is transferred to pan-
tothenate yielding PPan.
Type 2 PanK is typically found in Staphylococcus aureus and eukaryotic cells. While the
amino acid homology between type 1 and type 2 is not very high, they do share the same feedback
mechanism. The exception from this rule is S. aureus PanK where the feedback regulation of
CoA and its thioesters is lacking [9][10]. N-alkylpantotheamides belongs to a class of pantothen-
ate analogues that both type 1 and type 2 PanK are able to phosphorylate. The phosphorylation
will transform the N-alkylpantotheamides into inactive Coa analogues via the organism’s native
CoA biosynthetic pathway. These CoA analogues will act as antimetabolites and inhibitors of
bacterial growth [11].
Type 3 PanK, which occurs in a number of bacteria such as Pseudomonas aeruginosa and
Heliocabacter pylori, lacks any amino acid similarity to the other types. This enzyme is also
not feedback inhibited by CoA and its thioesters. This PanK forms a dimer (Figure 1.3). Unlike
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type 1 and type 2 PanK, type 3 PanK is not able to use N-alkylpantotheamides as substrates
and it has a very high Km for ATP (∼10 mM) [11]. Sequence alignment of the type 3 PanK
crystal structures from P. aeruginosa (PaPanK), Bacillus anthraci (BaPanK) and Burkholderia
cenocepacia (BcPanK) has shown a near perfect alignment of all major secondary strutural fea-
tures (-helices, -sheets and loop regions) suggesting that the structure of type 3 PanK is very
similar across bacteria. However, the alignment of the nucleotide binding site of type 3 PanK
from these bacteria has shown an alteration in the substrate-interacting loop region in BaPank
when compared to the other two bacteria species. Inhibitors of BaPank are also lacking activity
against PaPanK and BcPanK [11] [6].
Structural comparison between type 1 PanK from E.coli (EcPanK) and type 3 PanK from
Thermotoga maritima (TmPanK) may provide an explanation on why type 3 PanK does not
have the ability to use N-alkylpantotheamides as substrates and why it is lacking feedback inhi-
bition by CoA. A hypothesis claimed that a hydrophobic pocket that is mostly lined with aro-
matic residues, accommodates the hydrophobic tail of the N-alkylpantothenamides because this
pocket was shown to be able to accommodate the additional thiol group of CoA. Therefore, the
N-alkylpantothenamides can be used as a substrate by EcPanK and converted to antimetabolites
of CoA. Inspection of TmPanK did not show any hydrophobic pocket that could do the same,
which may explain why N-alkylpantothenamides are not inhibitors or substrates of type 3 PanK
and why type 3 PanK lacks feedback inhibition of CoA and its thioesters [12].
Pantothenate has shown to bind to PanK through multiple hydrogen bonds (Figure 1.4). Sev-
eral inhibitors for type 1 and type 2 PanK have been reported but very few inhibitors of type 3
PanK have been reported. One reported inhibitor for type 3 PanK is a ATP mimic with a Ki
of 164±3 M, which is 3-fold lower than the Km value of ATP (510 M). This inhibitor works
as a competetive inhibitor on BaPank but no bacterial growth inhibition was reported [13] [14].
The structure of PaPanK is known, therefore, structure-based methods for hit discovery can be
applied. One such methods is structure-based virtual screening.
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Figure 1.3: Structure of type 3 PanK from P. aeruginosa. The substrate, pantothenoic acid (pantothen-
ate), is shown in purple sticks. Hydrogen bonds are indicated as black dotted lines. PDB code: 2F9W
Figure 1.4: A zoomed in image of the structure of PaPanK (Figure 1.3) that shows the binding mode
of pantothenate. Pantothenate binds to PanK by forming hydrogen bonds with the residues Gly 99, Asp
101, Arg 102, Tyr 92 and Thr 180.
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1.5 Structure-based virtual screening
Structure-based virtual screening is a computational method to screen large libraries of chem-
icals against a biological target. The predicted compounds can then be experimentally tested
against the target in order to evaluate the predictions from the virtual screening (Figure 1.5) .
This form of screening is not without challenges, such as sampling the different conformations of
flexible molecules and calculation of the absolute energy for binding in aqueous environment.
Regardless, this field has shown success by predicting new ligands with their receptor-bound
structures, and in some cases, giving us hit rates that are greater than with high-throughput
screening [15].
Figure 1.5: In structural-based virtual screening, libraries of compounds are docked into the binding
site of the target molecule by a docking computer program. Each compound is sampled in thousands to
millions of possible configurations. Each configurations is then scored based on its complementarity to
the binding site. Ligands can then be ranked based on various factors such as torsion angles, inter- and
intra clashes and the interactions that the ligands form with the target. The best ranked ligands are then
chosen for testing for activity in an experimental assay.
In the initial phases of a virtual screening a database or a list of compounds needs to be
selected and then prepared. The database usually comes from suppliers with a collection of
compounds that are physically available, or are readily synthesizable and can be produced easily
once they have been selected from a virtual screen [16]. There are several rules applied to guide
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the selection of molecules that can be used in the early stages of drug discoveries. The most
popular rule is the Lipinski Rule of Five. The rule states that drug-like compounds are more
likely to be orally avaiable if they have a molecular weight lower than 500 g/mol, lipophilicity
(logP) lower than 5, less than five hydrogen bond donors and less than 10 hydrogen acceptors
[17]. Astex’s rule of 3 is an alternative guideline that reduces the various thresholds from 5 to
3. Astex’s rule of 3 states that the molecular weight of the compounds should be lower than 300
g/mol, the number of hydrogen bond donors and acceptors is ≤3, XlogP is ≤3, the number of
freely rotatable bonds is ≤3 and the polar surface area is ≤60 Å2 [18]. Other guidelines that can
be worth following in the early stages of drug discoveries is to remove compounds that have un-
wanted functionalities before screening. Compounds that possess potentially mutagenic groups
or are likely to have unfavourable pharmacokinetic properties are usually not desired. These
groups include nitro groups, thiols, sulfates and phosphates [19].
In structure-based virtual screening, the essence is to simulate molecular recognition events.
Therefore, it is necessary to prepare the database from its initial 2D form to a database with
3D coordinates. Compounds in a database are often registered in only one tautomer that is not
necessarily correct at the experimental pH, where a balanced tautomeric equilibria might exist.
Also, that tautomer might not be able to bind on the target molecule. Therefore, it is necessary
to consider all relevant tautomers and assign them to the compounds in the database since there
is no way of knowing beforehand which tautomer will most likely bind to the target molecule
[16].
Just like the database, the active site of the target molecule also needs preparation. Ioniz-
able residues in the active site have protonation states that need to be determined. In addition,
the right histidines tautomers must also be assigned. The next step is to dock each molecule in
the database into the binding site of the target. The binding mode is predicted by sampling the
coordinate space of the binding site and the quality of the generated poses are ranked based on
scoring functions [16].
A challenge with docking is the flexibility of the protein target. The binding pocket of the
target usually adapts to fit the ligands upon binding through various conformations and majority
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of docking tools assumes that the protein target is held fixed in its conformation. This assump-
tion is not accurate but because of the increased complexity of the binding, this assumption is
necessary. Water molecules also play a role in the binding between the ligand and the target
protein. Water molecules can form hydrogen bonds at the interface between the target and the
ligands and mediate ligand-target interaction. The location of water molecules may vary largely
among ligands. The role of water molecules in docking is very important but the accurate pre-
diction of the contribution from the water molecule is a long-standing challenge [20] [16].
1.6 FlexX
FlexX is a docking program that uses a docking algorithm based on an incremental construction
strategy. The first step of the docking algorithm is base selection. This step selects a fragment
used as a starting point and this fragment is called the base fragment. The next step is called
base placement. The main goal of this step is to dock the base fragment into the active site of
the protein and to find favorable interactions between the fragment and the protein. The third
and final step is reconstruction of the ligand in an incremental way [21].
The ranking of the generated solutions is performed by estimating the free binding en-
ergy ΔG of the protein-ligand complex. This scoring function is based on an empirical scor-
ing function developed by Böhm [22]. The ranking considers hydrogen bonds (ΔGhb), ionic
interactions(ΔGio), lipophilic protein-ligand contact surfaces (ΔGlipo), number of rotatable bonds,
the loss of entropy due to translational and rotational hindrance and aromatic interactions (ΔGaro).
f(ΔR,Δ ) is a scaling function that penalizes deviation from the ideal geometry and Nrot is the
number of free rotatable bonds that are immobilized in the complex [21].


















HYDE is a scoring function developed by Reulecke et al. [23] and is based on the estimation
of the free energies emerging from HYdrogen bonding and DEhydration during the binding
between protein and ligand. It describes the binding energies contributions of hydrogen bonding
and the hydrophobic effect that are energetically favorable, as well as polar desolvations that
energetically unfavorable. Overall, the purpose of the HYDE scoring function is to estimate
the change in saturation and desolvation between the bound and unbound molecules [24]. The







HYDE scoring can be visualized in the software Seesar. Atoms with the most favorable con-
tributions are coloured green, yellow for neutral and red for unfavorable contributions. For
example, atoms involved in a interaction with a good geometry are coloured green and atoms in
unfavorable regions are coloured red [25].
1.7 Protein crystallization
To determine the atomic and molecular structure of a protein, X-ray crystallography is often uti-
lized. A protein crystal is a necessity for this method. There is a variety of ways to form protein
crystals but finding the best conditions for crystallization for new protein is a difficult task. The
first step is to set up screening trials by exposing the protein to a number of different precipitant
agents. The screening can help to find hits that can be indicative for protein crystallization. In
such conditions protein may form crystals, crystalline precipitate or phase separation, and those
conditions are worth pursuing. Once a possible crystallization condition has been found, opti-
mization can be performed by varying the protein concentration, pH, temperature or by adding
additives [26]. Commercially available crystallization screening kits can be used as the first
choice when crystallization conditions are not known [27].
Vapour diffusion is the most common method for crystallization. The sample is either a
hanging or sitting drop containing a fixed ratio between both protein and reservoir solution.
This drop is then equilibrated against the reservoir solution that contains crystallization agents
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at higher concentration than the drop. To achieve equilibration, water vapour will diffuse be-
tween the drop and the reservoir promoting the supersaturation of the protein drop with protein
and crystal formation [26].
The information extracted from X-ray crystallography is a requirement for a structure-based
drug discovery project. This is because this information provides knowledge about the protein
structure which can be used to develop and optimize the inhibitors of that protein. A crystal
structure of a protein-inhibitor complex can pinpoint key interactions and this information can be
used for designing compounds that can improve the affinity and selectivity as well as compound
pharmacokinetis [28].
1.8 Aim of the study
Antibiotic resistance is a serious problem around the world and the problem is constanly increas-
ing. Therefore, the need of new antibiotics is very urgent, in particular for P.aeruginosa. The
overall aim of the project is to discover starting point for new antibiotics. PanK is an attractive
target for developing new antibiotics as PanK is essential for bacteria. Further, differences be-
tween the isoforms makes it likely that selctive inhibitor can be developped. Virtual screening
will be used to identify novel ligands that bind into the active side of PanK. Hit compounds from
the virtual screening will then be selected and tested experimentally, using X-ray crystallography
to verify their binding to the target and to guide the design of new PanK inhibitors. To enable




All chemicals were purchased from Sigma-Aldrich unless otherwise stated.
2.1 Transformation of cells and overexpression of PanK
E. coli C41 (DE3), C43 (DE3), BL21 (DE3), Rosetta (DE3), C41 pLYsS (DE3) and C43 pLYsS
(DE3) competent cells (Lucigen) were used to express the recombinant type 3 PanK from P.
aeruginosa. The vector pET-28a(+) (Genscript) was used for the expression of the protein.
This vector contains a kanamycin resistance gene as well as a gene sequence for the expression
of a N-terminal 6x histidine tag followed by a Tobacco Etch Virus (TEV) cleavage site (Figure
2.1). PanK gene was inserted into the plasmid using the Nhel/BamHl cloning sites.
1 L of stock plasmid (10-50 ng) was added to the competent cells and incubated on ice for
30 minutes. Cells were then heat shocked at 42◦C for 45 seconds followed by incubation on ice
again for 2 minutes. 950 L of Lysogeny Broth (LB) mediumwas added to the cells and the cells
were incubated at 37◦C for 1 hour at 250 rounds per minute (rpm) . 200 L of the cells were
plated on LB agar plates containing 50 g ml−1 kanamycin and incubated overnight at 37◦C.
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Figure 2.1: Vector used to express PanK with 6x histidine tag and a TEV site. The cloning sites of PanK
is on NheI/BamHI (sequence of PanK not shown).
A single colony from freshly transformed cells was incubated in 10 mL of LB-medium con-
taining the same concentration of kanamycin while shaking at 37◦C overnight and then aliquoted
and stored in −80◦C for future use. 100 L of the stock of transformed cells were incubated in
100 mL of LB-medium containing the same concentration of kanamycin while shaking at 37◦C
overnight. The overnight culture was then transferred to 900 mL of LB-medium containing the
same concentration of kanamycin and incubated until the OD600 reached 0.8-1.0. Isopropyl--
D-1-thiogalactoside (IPTG) induction agent with a final concentration of 1 mM was added to
the cultures which was further incubated for 3 hours at 37◦C while shaking. The culture was
centrifuged at 5000 x g for 10 minutes at 4◦C. Supernatant was removed and the cell pellet was
flash frozen with liquid nitrogen and stored at −80◦C.
2.2 Purification of PanK
Purification of PanK was achieved in a similar way to [9] using affinity chromatography, 6-His
tag cleavage with TEV protease and finally size exclusion chromatography. Cell pellets from the
cell line E. coli C41 (DE3) were first thawn on ice and resuspended in lysis buffer containing 20
mM Tris pH 7.9, 500 mM NaCl, 20 mM imidazole and 10% (v/v) glycerol supplemented with 2
tablets of Complete EDTA-free protease inhibitor cocktail (Roche) and 40 L of DNase 1. The
cells were sonicated for a total of 2 minutes with 10 seconds pulses followed by centrifugation
at 15000 rpm for 30 minutes. The supernatant was collected and filtered through a 0.2 m filter.
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All purifications were performed on an ÄKTA pure instrument (GE Healthcare) at room tem-
perature. The protein was purified by binding to a HisTrap HP 5 mL column (GE Healthcare).
After loading, the column was washed with 3 column volumes (CVs) of lysis buffer (20 mM
Tris-HCl, 500 mM NaCl, 20 mM imidazole 10% (v/v) glycerol, pH 7.9) and then the bound
protein was eluted by using 0-100% gradient on 15 CVs of elution buffer (20 mM Tris-HCl, 500
mM NaCl, 500 mM imidazole, 10% (v/v) glycerol, pH 7.9).
The imidazole was removed by buffer exchange against gel filtration buffer (50 mM Tris-
HCl, 150 mMNaCl, pH 7.5) by using Amicon® Ultra centrifuge filters (Merck) with a molecular
weight (MW) cut-off of 10 kD. The protein fractions were concentrated using the same filters
and concentration was measured by using a Nanodrop. Purified TEV protease with a ratio of
1:100 (mg of TEV: protein) was added to the protein and incubated at 4◦C with shaking in order
to cleave the TEV site in the protein. The same column as in the previous step was washed with
3 CVs of gel filtration buffer and followed by 5 CVs of the same elution buffer. His-tag cleaved
protein was collected in the flow through fractions. The fractions were concentrated to a final
volume ≈ 2 mL by centrifugation at 4000 rpm for 20 min. Size exclusion chromatography was
performed by loading the fractions onto a HiLoad 26/600 Superdex 75 column equilibrated with
gel filtration buffer. The column was eluted with 1.2 CV with gel filtration buffer. The concen-
tration of the protein was determined by a NanoDrop® 1000 Spectrophotometer (Thermo Fisher
Scientific) using an extinction coefficient of 0.677 (mg/mL)-1 cm-1. In addition, A His-tag affin-
ity chromatography purification attempt replacing Tris-HCl with 100 mM sodium phosphate
buffer (pH 6.5) with the same additives was all also conducted.
2.3 Gel electrophoresis
The purity of the PanK after each purification step was checked by using SDS-PAGE (Sodium
Dodecyl Sulfate–PolyacrylamideGel Electrophoresis) usingAny kDTM Mini-PROTEAN® TGXTM
Precast Protein Gels (Biorad) with 2 M of dithiothreitol (DTT) . The MW of protein bands was
assigned by using Precision Plus ProteinTM Dual Color Standards (Biorad). Electrophoresis
was run for 30 minutes at 200 V. Gels were stained using InstantBlueTM Ultrafast Protein Stain
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(Merck). A tiny piece of gel containing the protein was then cut off and send to the University
of Oulu for a MALDI-TOF mass spectrometry analysis in order to confirm the identity of the
protein.
2.4 Dynamic light scattering
Dynamic light scattering (DLS) is a technique used to determine distribution profile of polymers
in a solution. This technique can determine if the purified protein aggregates in the solution.
Before the DLS measurement, the refractive index of the sample was measured in triplicate us-
ing Abbemat 500 refractometer (Anton Paar). 70 L of purified PanK solution was pipetted
into a disposable cuvette. The sample was measured in the DLS instrument (Malvern). The
measurement was conducted at 4◦C, in triplicate and with a delay of 10 seconds between each
measurement.
2.5 Protein thermal shift assay
A protein thermal shift assay was conducted in order to find out which buffers and additives
stabilize or destabilize PanK. This method monitors the temperature dependent protein unfold-
ing by letting the fluorescent dye SYPRO orange bind to the hydrophobic region of the protein.
When the protein is unfolded due to the increased temperature, SYPRO orange will bind to the
exposed hydrophobic region which will result in a large increase in fluorescence.
The Rubic buffer screen kit (Molecular Dimension) was used for the first experiment. 21 L
of buffer and 2 L of purified Pank with a initial concentration of 2.88 mg/ml was pipetted to
a 384-well plate. Stock solution of SYPRO orange (Merck) was prepared by diluting 15.5 L
of 5000X to a final concentration of 155X with water, making a 50 L stock solution. 2 L of
the prepared stock solution of SYPRO orange was added to each well that contained buffer and
PanK. The plate was sealed using the semi automated plate sealer from Axygen® PlateMax® and
the plate was heated from 20◦C to 95◦C with a heating rate of 0.04◦C/s by using the LightCycler
®480 II (Roche). The Rubic additive screen kit (Molecular Dimension) was used for the second
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experiment. 16 L of Rubic additive screen and 5 L of buffer chosen from the first experiment
were pipetted to a 384-well plate. PanK and SYPRO Orange were kept at the same concentra-
tion as in the first experiment. 2 L of both solutions were pipetted to the plate making a 25 L
solution in the wells. The plate was sealed and heated in the same way as in the first experiment.
2.6 Crystallization of PanK
Purified PanK was concentrated to around 5 mg/ml in 100 mM sodium citrate pH 6.0, 250 mM
NaCl, 1 mM tris(2-carboxyethyl)phosphine (TCEP), 5 % glycerol (v/v) for the crystallization
trials. Trials were set up with the sitting-drop vapor diffusion method using Mosquito© HV
(Sptlabtech) in Swissci 96-Well 3-Dropa well plates. Drops containing 2l of PanK were mixed
with reservoir solution in a ratio of 1:1, 1:2 and 1:3 (volume PanK: volume reservoir solution).
As reservoir solutions the following crystallization kits were used: JCSG-plus™(Molecular Di-
mension), Ligand-Friendly screen (Molecular Dimension), Pact premier™(Molecular Dimen-
sion) and AmSo4 (Qiagen). All crystals were grown in 20◦Cwith the exception of one plate that
contained His-tag PanK that were grown in 8◦C. Crystals typically appeared within one week
in form of needles and prior to to data collection, crystals were transferred to cryoprotectant
solutions containing 50% glycerol before flash-freezing in liquid nitrogen. Crystals were send to
Diamond synchrotron facility (United Kingdom) and Max IV laboratory (Sweden) for diffrac-
tion.
2.7 Setup for docking
The crystal structure of the PanK in complex with pantothenate (PDB code: 2F9W) was pre-
pared with the software SeeSAR ver. 9.2 (BiosolveIT, Germany) in order to use it as a receptor
for docking. The binding site was defined as the residues around pantothenate plus the adja-
cent pocket for the binding of ATP in chain A as defined by th SeeSAR pocket finder algorithm
(Figure 2.2).Two different setups were used. In one setup, a carboxylate group was required
and in the other setups, a hydrophobic group was required. Both groups were placed inside a
sphere with a radius of 2.5 Å around C8 of pantothenate in chain A. This was done to ensure
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that the ligands are placed in the pan binding site in order to make sure that the ligands are
docked into the pantothenate binding site. Both setups were validated by redocking pantothen-
ate a hydrophobic group requirement with a radius of 2.5 Å was generated around C8 of chain A.
Figure 2.2: Binding site of PanK as defined by SeeSAR pocket algorithm. The binding site is located at
the cloudy space.
2.8 Database for virtual screening
An in-house MySQL database of around 6 million commercially available compounds was pre-
pared. The compounds were obtained from Otava chemicals, Asinex, Chembridge, Chemdiv,
Enamine, Interbioscreen, Key Organics, LifeChemicals, Specs, Timtec and Vitas. Using in-
house scripts based on the RDkit, unique smiles for all compounds, stereosisomers and physico-
chemical properties were calculated. From these compounds, the libraries were prepared, one
containing carboxylates and one containing diverse molecules. Both libraries were obtained us-
ing the following filters: 28 heavy atoms or less, 1 or more hydrogen bond donor and acceptor,
7 or more rotatable bonds, 3 ring systems or less, maximum 2 fused rings, 2 or more atoms that
are not part of a ring system, maximum 1 nitrile group, 2 ether group or less, a total charge be-
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tween -2 and 2 and xlogp value between 2 and -3. This resulted in 975408 unique compounds in
both libraries. For the carboxylate library, compounds were filtered for those that contain a car-
boxylate group using in-house scripts based on RDkit. This resulted in 89305 compounds with
carboxylate group. Using in-house scripts based on RDkit, a total amount of 162888 stereoiso-
mers for docking were generated for these compounds. For the diverse library, a total amount
of 1977327 stereoisomers for docking were generated.
2.9 Docking
For the docking, FlexX 4.0 was used for filtering the HYDE scoring. For each compound the
best binding pose was saved. The pose which got a score of ≤ -20.0 were subsequently scored
with HYDE. Docked ligands that had a predicted ligand-lipophilicity efficiency (LLE) of ++
were kept. If the ligand had more than one pose that scored with LLE of ++, the one with
the better predicted binding affinity was kept The compounds were then loaded into the soft-
ware Maestro ver. 11.9 for visual inspection. Pharmacophore hypotheses were derived based
on the retrieved structures. The pharmacophore hypothesis derived from the carboxylate group
featured one negative ionic group, one positive ionic group and one hydrogen bond donor that
points Asp101. The pharmacophore hypothesis derived from the diverse group used the same
features as the carboxylate group, except the negative ionic group was replaced with a hydrogen
bond acceptor. A second pharmacophore hypothesis was develop in the diverse group by remov-
ing the hydorgen bond acceptor and include an excluded group with a radius of 1.0 Å derived
from the carboxylate group from the pantothenate in chain A. All pharmacophore features have
a radius of 2.0 Å. A total amount of 20 compounds were selected for future hit validation (Table
3.18 and Table 3.19).
32 CHAPTER 2. MATERIALS AND METHODS
Chapter 3
Results
3.1 Overexpression of PanK
First, suitable conditions to overexpress PanK were established. Six different E.coli cell lines
were tested, namelly C41 (DE3), C43 (DE3), C41 pLYsS (DE3), C43 pLYsS (DE3), BL21
(DE3) and Rosetta (DE3). All cell lines were transformed with the plasmid of interest and 100
mL test cultures were grown as described in the previous chapter. After sonication and centrifu-
gation, the supernatant and cell lysates were tested for the expression of desired protein via SDS
electrophoresis.. As control, the corresponding samples of cell cultures that were not induced
for protein expression were also added to the gels. The main goal of this experiment is to find out
which cell lines are most suitable to express PanK. His-tag PanK has a MW of 29.45 kD. From
the SDS-page (Figure 3.1), it can be observed that C41 pLYsS and C43 pLYsS do not seem to
express much PanK as the other cell lines, therefore, not suitable for expressing PanK. The other
cell lines showed a better expression of PanK, therefore, they were used for subsequently used
to overexpress PanK for protein purification.
3.2 Purification of PanK
Next, a suitable purification protocol was established. The purification strategy is adapted from
[9]. The strategy of the first purification (His-tag affinity chromatography) is to isolate His-
tag PanK from other undesired proteins by letting it bind to the nickel resin via the His-tag in
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the column. Once the other undesired proteins have passed the column and ended up in the
flowthrough, the bound His-tag Pank can then be eluted from the column by letting the elution
buffer to pass through the column. The elution buffer contains a high concentration of imidazole
which competes with His-tag PanK for binding to the nickel resin in the column. The next pu-
rification step is to cleave the TEV -site and the His-tag from PanK. After PanK was incubated
with TEV-protease, the His-tag and the TEV -site were cut from PanK and PanK can be isolated
by loading the sample onto the same column. The TEV-cleavage site and TEV will attach to the
nickel resin in the column via the His-tag and PanK will pass through the column. As a final
step of the purification protocol, a size exclusion chromatography was conducted. This step is
for polishing the purity of PanK and to separate PanK from potential protein aggragate that may
have formed during the purification.
Between each purification step, the fractions were analyzed using gel electrophoresis in or-
der to confirm the purity of the fractions. The samples on the first gel (Figure 3.2 A) are from the
first purification (his-tag affinity chromatography). Lane 2 is the elution fraction that contained
the purified his-tag PanK. As mentioned before His-tag PanK has a MW of 29.45 kD and pro-
teins can be observed between the 25 kD and 37 kDmark which indicates that PanK was located
in the fraction where it is expected to be in. Lane 3-6 are the flow-through fractions. Undesired
proteins can be observed in these fractions and most of them cannot be observed in the elution
fraction which is expected. The second gel (Figure 3.2 B) contains samples from the second pu-
rification (Cleavage of TEV -site). Lane 2 is the TEV-protease used to the cut the TEV-cleavage
site, lane 3 is the loading sample that was loaded into the HisTrap HP 5 mL column, lane 4 is
His-tag PanK before incubation with TEV-protease, lane 5-6 are the flowthrough and lane 7 is
the elution. Protein can be observed around the 25 kD mark in lane 6 as expected for PanK.
No other proteins can be observed in lane 6 which indicates that the purification managed to
separate Pank from other undesired proteins. The third and final gel (Figure 3.3 A) contains
the sample from the size exclusion chromatography. Lane 4 is the fraction collected from the
purification. A simple band was visible around 25 kD corresponding to PanK. A typical yield
of PanK after size exclusion chromatography was around 0.82 mg/l cell culture. Results from
the MALDI-TOF mass spectrometry confirmed the molecular mass of the to be 27.241002 kD
which matches with theoretical value (27.24151 kD) of PanK. Purification attempt using 100
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mM sodium phosphate (pH 6.5) was conducted because this buffer appeared to be able to stabi-
lize PanK better than Tris-HCl which will be discussed later (Table 3.1). Purified His-tag PanK
is most likely located in lane 9 due to a simple band was visible around 25 kD in that lane (Figure
3.3 B). Compared to the His-tag affinity chromatography using Tris-HCl as buffer (Table 3.2 A),
the purity of the protein appeared to be better as no other proteins can be observed in lane 9.
Figure 3.1: SDS-PAGE from the test cultures. His-tag PanK has a MW of 29.45 kD, which means PanK
is located between the 25 kD and 37 kD mark. A: SDS-PAGE that contained samples from the cell line
C43 (DE3), BL21 (DE3) and Rosetta (DE3). Lane 2-5 contained the cell line C43 (DE3). Lane 2 was
the pre-induced supernatant, lane 3 was the pre-induced cell lysate, lane 4 was the induced supernatant
and lane 5 was the induced cell lysate. Lane 6-9 contained the cell line BL21 (DE3). Lane 6 the was
pre-induced supernatant, lane 7 was the pre-induced cell lysate, lane 8 was the induced supernatant and
lane 9 was the induced cell lysate. Lane 10-13 contained the cell line Rosetta (DE3). Lane 10 was the
pre-induced supernatant, lane 11 was the pre-induced cell lysate, lane 12 was the induced supernatant and
lane 13 was the induced cell lysate. B: SDS-PAGE that contained samples from C41 pLYsS (DE3), C43
pLYsS (DE3) and C41 (DE3). Lane 2-5 contained the cell line contained the cell line C41 pLYsS (DE3).
Lane 2 was the pre-induced supernatant, lane 3 was the pre-induced cell lysate lane 4 was the induced
supernatant and lane 5 was the induced cell lysate. Lane 6-9 contained the cell line C43 pLYsS (DE3).
Lane 6 the was pre-induced supernatant, lane 7 was the pre-induced cell lysate, lane 8 was the induced
supernatant and lane 9 was the induced cell lysate. Lane 10-13 contained the cell line C41 (DE3). Lane
10 was the pre-induced supernatant, lane 11 was the pre-induced cell lysate, lane 12 was the induced
supernatant and lane 13 was the induced cell lysate.
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Figure 3.2: A: SDS-PAGE from the His-tag affinity chromatography. Lane 1 is the protein standard
while lane 2 and lane 3-6 are the elution and flow-through fractions respectively. B: SDS-PAGE from
the cleavage of the TEV site. Lane 1 is the protein standard, lane 2 is the TEV protease used to cut the
TEV-site in PanK, lane 3 is the loading sample that was purified, lane 4 is His-tag PanK before incubation
with TEV protease and column and lane 5-6 and 7 are the elution and flowthrough respectively.
Figure 3.3: SDS-PAGE from the size exclusion chromatography and His-tag affinity chromatography
using phosphate as lysis and elution buffer. Gel on the right was to the size exclusion chromatography
while the gel to theleft is from the His-tag affinity chromatography. A: Lane 4 was the protein standard
while lane 5 was the elution. B: Lane 1 was the protein standard, lane 2 was the loading sample, lane 3-7
were the flowthrough while lane 8 and 9 were the elutions.
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3.3 Dynamic light scattering
For the protein crystallization, the protein should not form aggregates. Therefore, DLS used
for measuring the size distribution of PanK when it is dissolved in the gel-filtration buffer in
order to find any potential protein aggregations. The sample was measured in triplicates with
a delay of 10 seconds between each measurements. The results are presented in the form of an
intensity curve and a correlogram. Multiple peaks intensity curve were observed (Figure 3.4 A).
The peak with the highest intensity is located around the 10 nm mark and corresponded likely
to non-aggregated PanK. In addition, peaks at 100 nm and 1000 nm can be observed, indicating
aggregates. The correlogram (Figure 3.4 B) is also not very ideal as a "bump" can be observed
which could indicate aggregation in the sample. Because of the potential aggregates discovered
in Tris-HCl buffer, a new buffer was needed. A thermal shift assay was therefore conducted.
Results from the thermal shift assay suggested that citrate buffer at pH 6.0 was a better buffer
for PanK (Table 3.1). A new DLS experiment was conducted using citrate as a buffer for PanK
(Figure 3.5). The highest peak can again be observed around 10 nm which further suggested
that that this peak was non-aggregated PanK. Additional peaks could also be observed around
1 nm and between 100 nm and 1000 nm (Figure 3.5 A). These peaks could indicate aggregates
but compared to intensity curve from Tris-HCl (Figure 3.4 A), citrate looked much better. The
correlogram also appeared to have improved as no "bump" could be observed (Figure 3.5 B).
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Figure 3.4: Obtained data from the DLS experiment using Tris-HCl as the buffer for PanK. The experi-
ments was conducted in triplicates. A: Intensity curve. B: Correlogram.
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Figure 3.5: Obtained data from the DLS experiment using citrate as the buffer for PanK The experiment
was conducted in triplicates. A: Intensity curve. B: Correlogram
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3.4 Thermal shift assay
In the next experiment, buffer screen with 96 different conditions was conducted in order to find
which buffer stabilizes PanK. This section shows the shift of the melting temperatures (ΔTm)
of PanK in the different buffers. The reference temperature was 56◦C and was determined with
PanK dissolved in water. The buffers are sorted according to the different buffer groups provided
by the supplier.
The main purpose of the buffer and pH screens (Table 3.1) is to find what combination of
buffer and pH is most stabilizing for the protein. Phosphate buffers and citric acid buffer stabi-
lized PanK most among all buffers that were listed in this table. The pH of the buffer had also
an impact on the stability of the protein. This could be observed from the by using citric acid
buffer with a different pH. While a citric acid buffer with a pH of 4.0 destabilizes PanK by ΔTm
-12.19, the same buffer at pH 6.0 stabilized the protein by ΔTm 2.81. Tris-HCl with a pH-value
of 7.5 is the buffer used as gel filtration buffer for PanK. While this buffer stabilized the PanK
by ΔTm by 1.77, aggregation has been observed when using this buffer (Figure 3.4). Phosphate
buffers and citric acid at a pH -value of 6.0 appeared to be a better choice for PanK.
The purpose of the next set of buffers (Table 3.2) was to observe the change in ΔTm when
NaCl was added. The addition of salt in the citric acid buffers was less stabilizing for PanK with
the exception when the pH was 6.0. For the phosphate buffers, the addition of NaCl improved
the stability of PanK by ΔTm 4.20 for di-sodium phosphate and 4.12 for potassium phosphate.
The result from determining the thermal shift effect caused by different salt concentration (Table
3.4) supported the finding that NaCl contributed to the stabilization of PanK as ΔTm increases
as a function of NaCl concentration.
The result from the SPG buffer (Table 3.3) showed the effect of pH on PanK stability, un-
coupled to differences on ionic strength, salt or buffer systems used. From pH 4 to 4.5 it could
be observed that PanK was less stable while from pH 5.0 to pH 6.5, the stability of PanK iin-
creased with the pH -value. A pH of 6.0 to 6.5 appeared to be the best for the stability of PanK.
Increasing the pH further decreased the ΔTm of PanK.
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The final set (Table 3.6) was carried out to determine the thermal shift effect by experi-
menting with differen buffers and imidazole. Most buffer systems did not seem to be to able to
stabilize PanK with the exception of the buffer system 50 mM sodium phosphate/citric acid pH
7.5, 50 mM imidazole + 100 mM NaCl pH 7.5 and 125 mM imidazole + 100 mM NaCl pH
7.5 which slightly improved the stability. However, ΔTm decreased as a function of the concen-
tration of imidazole, which indicates that a high amount of imidazole was not suitable for the
stabilization of PanK.
Next, an additive screen was conducted in order to find out which additives can contribute to
the stabilization of PanK. The experiment was conducted with two buffers based on the buffer
screen. The two buffers chosen for this experiment were Tris-HCl pH 7.5 and citric acid pH 6.0.
A reference melting temperature was made for each buffer. The reference melting temperature
for PanK in citric acid was 56.87◦C and in Tris-HCl 55.44◦C.
The result from testing the thermal shift effect from salts ( Table 3.7) showed that most tested
salts were able to stabilize PanK though there were some salts that appeared to have a greater
buffer depending thermal shift effect on PanK, such as magnesium sulfate as the results from this
salt were different between the two buffers that were tested. The results from the monovalent
ions (Table 3.8) showed that most salts in this category contributed to the stabilization of PanK
with the exception of the iodide salts.
The results from the chaotropic agents (Table 3.9) showed that urea was not a good candidate
for stabilization of PanK. Urea has been widely used for protein denaturation [29]. The fact that
urea destabilized PanK should therefore be expected. Guanidine-HCl is also known to denature
proteins [30] though the results suggested that a concentration of 150 mM could actually stabi-
lize PanK to some degree.
Both TCEP and DTT (Table 3.16) are known for being reducing agents for protein. DTT is
a reducing agent normally used in protein research but it is also known for being very unstable.
TCEP is a reducing agent used for the same purpose as DTT but TCEP is more stable. Both
reducing agents stabilized PanK slightly but TCEP is better. Imidazole (Table 3.17 was already
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known for being unable to stabilize PanK at higher concentration based on previous results (Ta-
ble 3.6). As for the other additives, with a few exceptions, most of them are able to stabilize
PanK to some degree.
Table 3.1: The thermal shift effect of buffer and pH (low ionic strength)
Buffer ΔTm (in °C)
100 mM Citric acid pH 4.0 -12.19
100 mM Sodium acetate pH 4.5 -6.20
100 mM Citric acid pH 5.0 0.75
100 mM MES pH 6.0 -1.64
100 mM Potassium phosphate pH 6.0 2.42
100 mM Citric acid pH 6.0 2.81
100 mM Bis-Tris pH 6.5 0.87
100 mM Mes pH 6.5 -0.01
100 mM Di-sodium phosphate (monobasic) pH 7.0 2.70
100 mM Potassium phosphate (dibasic) pH 7.0 2.16
100 mM HEPES pH 7.0 0.18
100 mM MOPS pH 7 -0.13
100 mM Ammonium acetate pH 7.3 2.42
100 mM Tris-HCl pH 7.5 1.77
100 mM Imidazole pH 7.5 -0.69
100 mM HEPES pH 8.0 -1.24
100 mM Tris-HCl pH 8.0 0.67
100 mM Tricine pH 8.0 -0.52
100 mM Bicine pH 8.0 -0.55
100 mM Bicine pH 8.5 -1.96
100 mM Tris-HCl pH 8.5 0.53
100 mM CHES pH 9.0 -5.02
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Table 3.2: The thermal shift effect of buffer and pH (high ionic strength)
Buffer ΔTm (in °C)
Water + 250 mM NaCl 2.98
100 mM Citric acid + 250 mM NaCl pH 4.0 -15.69
100 mM Sodium acetate + 250 mM NaCl pH 4.5 -7.41
100 mM Citric acid + 250 mM NaCl pH 5.0 -0.37
100 mM MES + 250 mM NaCl pH 6.0 1.99
100 mM Potassium phosphate + 250 mM NaCl pH 6.0 4.57
100 mM Citric acid + 250 mM NaCl pH 6.0 4.77
100 mM Bis-Tris + 250 mM NaCl pH 6.5 3.30
100 mM Mes + 250 mM NaCl pH 6.5 3.42
100 mM Di-sodium phosphate + 250 mM NaCl pH 7.0 4.20
100 mM Potassium phosphate + 250 mM NaCl pH 7.0 4.12
100 mM HEPES + 250 mM NaCl pH 7.0 3.20
100 mM MOPS + 250 NaCl pH 7.0 2.93
100 mM Ammonium acetate + 250 mM NaCl pH 7.3 3.73
100 mM Tris-HCl + 250 mM NaCl pH 7.5 2.83
100 mM Di-sodium phosphate + 250 mM NaCl pH 7.5 3.61
100mM Imidazole + 250 mM NaCl pH 7.5 1.73
100 mM HEPES + 250 mM NaCl pH 8.0 1.40
100 mM Tris-HCl + 250 mM NaCl pH 8.0 2.47
100 mM Tricine + 250 mM NaCl pH 8.0 1.69
100 mM Bicine + 250 mM NaCl pH 8.0 2.19
100 mM Bicine + 250 mM NaCl pH 8.5 1.54
100 mM Tris-HCl + 250 mM NaCl pH 8.5 -1.50
100 mM CHES + 250 mM NaCl pH 9.0 2.79
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Table 3.3: The thermal shift effect of pH (same buffer)
Buffer ΔTm (in °C)
100 mM SPG pH 4.0 -13.86
100 mM SPG pH 4.5 -5.14
100 mM SPG pH 5.0 2.12
100 mM SPG pH 5.5 2.12
100 mM SPG pH 6.0 2.10
100 mM SPG pH 6.5 2.28
100 mM SPG pH 7.0 1.14
100 mM SPG pH 7.5 0.61
100 mM SPG pH 8.0 0.31
100 mM SPG pH 8.5 -0.18
100 mM SPG pH 9.0 -0.33
100 mM SPG pH 10 -4.56
Table 3.4: The thermal shift effect of ionic strength (salt)
Buffer ΔTm (in °C)
50 mM HEPES + 50 mM NaCl pH 7.5 0.96
50 mM HEPES + 125 mM NaCl pH 7.5 -0.08
50 mM HEPES + 250 mM NaCl pH 7.5 1.84
50 mM HEPES + 500 mM NaCl pH 7.5 4.31
50 mM HEPES + 750 mM NaCl pH 7.5 2.80
50 mM HEPES + 1000 mM mM NaCl pH 7.5 6.60
50 mM Tris-HCl + 50 mM NaCl pH 8.0 1.00
50 mM Tris-HCl + 125 mM NaCl pH 8.0 0.39
50 mM Tris-HCl + 250 mM NaCl pH 8.0 2.33
50 mM Tris-HCl + 500 mM NaCl pH 8.0 4.26
50 mM Tris-HCl + 750 mM NaCl pH 8.0 5.51
50 mM Tris-HCl + 1000 mM NaCl pH 8.0 6.56
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Table 3.5: The thermal shift effect of ionic strength (buffer)
Buffer ΔTm (in °C)
20 mM HEPES pH 7.5 0.18
50 mM HEPES pH 7.5 -0.04
125 mM HEPES pH 7.5 -0.53
250 mM HEPES pH 7.5 -0.48
20 mM Di-sodium phosphate (dibasic) pH 7.5 0.10
50 mM Di-sodium phosphate (dibasic) pH 7.5 0.81
125 mM Di-sodium phosphate (dibasic) pH 7.5 2.03
250 mM Di-sodium phsophate (dibasic) pH 7.5 5.21
20 mM Tris-HCl pH 8.0 0.09
50 mM Tris-HCl pH 8.0 0.34
125 mM Tris-HCl pH 8.0 0.97
250 mM Tris-HCl pH 8.0 1.90
Table 3.6: The thermal shift effect of buffer system and imidazole
Buffer ΔTm (in °C)
50 mM MES/Bis-Tris pH 6.0 -0.66
50 mM MES/ Imidazole pH 6.5 -0.96
50 mM Bis-Tris/PIPES pH 6.5 -0.58
50 mM MOPS/Bis-Tris propane pH 7.0 -0.31
50 mM Sodium phosphate/citric acid pH 7.5 0.59
50 mM MOPS/ HEPES-Na pH 7.5 0.02
0.1 M Bicine/ Trizma Base pH 8.5 -1.10
50 mM Imidazole + 100 mM NaCl pH 7.5 1.12
125 mM Imidazole + 100 mM NaCl pH 7.5 0.62
250 mM Imidazole + 100 mM NaCl pH 7.5 -0.47
350 mM Imidazole + 100 mM NaCl pH 7.5 -1.84
500 mM Imidazole + 100 mM NaCl pH 7.5 -3.80
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Table 3.7: Thermal shift effect from salts
Salts ΔTm (in °C) in citric acid ΔTm (in °C) in Tris-HCl
100 mM Sodium acetate 1.76 1.95
100 mM Calcium acetate 2.72 0.91
100 mM Potassium acetate 2.12 1.90
100 mM Ammonium acetate 1.75 1.79
100 mM Sodium sulfate 2.39 2.84
100 mM Magnesium sulfate 1.78 4.50
100 mM Potassium sulfate 0.68 0.93
100 mM Ammonium sulfate 2.51 2.76
100 mM Sodium phosphate (monobasic) 2.37 1.15
100 mM Sodium phosphate (dibasic) 1.07 0.80
100 mM Potassium phosphate (monobasic) 1.90 1.67
100 mM Potassium phosphate (dibasic) 0.93 1.31
100 mM Sodium tartrate 1.39 1.80
100 mM Sodium citrate (tribasic) 1.83 1.23
100 mM Sodium malonate 1.57 2.01
100 mM Sodium nitrate 0.53 0.60
100 mM Sodium formate 1.32 1.68
100 mM Potassium formate 1.30 0.69
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Table 3.8: The thermal shift effect from monovalent ions
Monovalent ions ΔTm (in °C) in citric acid ΔTm(in °C) in Tris-HCl
100 mM Sodium fluoride 1.63 1.89
100 mM Potassium fluoride 1.65 1.62
100 mM Ammonium fluoride 1.64 1.74
100 mM Lithium chloride 1.17 0.85
100 mM Sodium chloride 1.32 1.54
100 mM Potassium chloride 1.41 0.51
100 mM Ammonium chloride 1.13 1.27
100 mM Sodium iodide -4.17 -1.00
100 mM Potassium iodide -4.14 1.37
100 mM Sodium bromide 0.87 0.92
Table 3.9: The thermal shift effect from chaotropic agents
Chaotropic agents ΔTm(in °C) in citric acid ΔTm (in °C) in Tris-HCl
0.1 M Urea -0.10 0.13
0.5 M Urea 1.07 -0.84
1 M Urea -2.35 -3.42
2 M Urea -5.75 -9.89
4 M Urea -21.09 -30.94
150 mM Guanidine-HCl 0.33 0.81
500 mM Guanidine-HCl -0.13 -0.88
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Table 3.10: The thermal shift effect from Non detergents and detergents
Non detergents, detergents ΔTm (in °C) in citric acid ΔTm (in °C) in Tris-HCl
1 mM NDSB-195 0.27 0.37
1 mM NDSB-201 0.27 -0.07
1 mM Fos Choline 12 -10.16 -2.34
1 mM CHAPS -0.11 0.02
1 mM CHAPSO -0.07 0.02
1 mM OG -0.18 -0.11
1 mM DM 2.50 -1.07
1 mM DDM 9.19 -5.82
Table 3.11: The thermal shift effect from Carbohydrates
Carbohydrates ΔTm (in °C) in citric acid ΔTm (in °C) in Tris-HCl
25 mM Monosaccharides mix MD2-100-75 0.47 0.58
25 mM Glucose 0.33 0.35
25 mM Sucrose 0.62 0.13
25 mM Maltose 0.65 0.25
Table 3.12: The thermal shift effect from polyols
Polyols ΔTm (in °C) in citric acid ΔTm (in °C) in Tris-HCl
5%(v/v) DMSO -0.72 -1.19
5%(v/v) Ethylene glycol -0.25 0.33
5%(v/v) Glycerol 1.50 0.92
20%(v/v) Glycerol 3.45 2.88
5%(v/v) PEG 400 -0.02 -1.34
5%(w/v) PEG 1000 0.26 0.58
5%(w/v) PEG 3350 0.25 -0.69
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Table 3.13: The thermal shift effects from Carboxylic acids and amino acids
Carboxylic acids, amino acids (racemic) ΔTm (in °C) in citric acid ΔTm (in °C) in Tris-HCl
50 mM Carboxylic acids mix MD2-100-76 1.28 1.01
50 mM Proline 0.56 0.42
50 mM Glycine 0.74 0.72
50 mM Glutamic acid 1.10 1.08
500 mM Glutamic acid 3.39 3.84
50 mM Arginine -3.94 -0.36
500 mM Arginine -14.15 -9.93
50 mM Arginine + 50 mM Glutamic acid -2.19 0.01
500 mM Arginine + 500 mM Glutamic acid -3.33 -0.76
50 mM Gly-Gly-Gly 0.51 0.15
5 mM Oxoloacetic acid 0.06 0.40
Table 3.14: The thermal shift effects from Co-factor and polyamines
Co-factor, polyamines ΔTm (in °C) in citric acid ΔTm(in °C) in Tris-HCl
5 mM Biotin 0.28 0.49
5 mM Betaine 0.53 0.81
5 mM Coenzyme A 0.70 0.19
5 mM Nicotinic acid 0.32 0.55
1 mM Spermidine 0.30 0.28
1 mM Spermine -0.07 0.31
1 mM Sarcosine 0.33 0.28
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Table 3.15: The thermal shift effects Nucleotides
Nucleotides ΔTm (in °C) in citric acid ΔTm (in °C) in Tris-HCl
∼20 M Deoxyribonucleic acid library < 50 bp 0.65 0.49
1 mM ATP + 1 mM magnesium chloride 0.38 0.65
1 mM ATPS + 1 mM magnesium chloride 0.82 0.89
1 mM cAMP + 1 mM magnesium chloride 0.37 0.32
1 mM GTPS + 1 mM magnesium chloride 0.69 0.37
1 mM cGMP + 1 mM magnesium chloride 0.80 0.48
1 mM NADH + 1 mM magnesium chloride 0.16 0.48
1 mM NADPH + 1 mM magnesium chloride 0.41 0.47
5 mM Polyethylenimine -2.40 -1.17
Table 3.16: The thermal shift effects from reducing agents
Reducing agents ΔTm(in °C) in citric acid ΔTm (in °C) in Tris-HCl
5 mM DTT -0.09 0.20
5 mM TCEP 0.81 0.51
Table 3.17: The thermal shift effects from imidazoles
Imidazoles ΔTm(in °C) in citric acid ΔTm (in °C) in Tris-HCl
200 mM Imidazole -4.76 -3.78
400 mM Imidazole -10.45 -8.36
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3.5 Crystallization
In order to cellect data from the structure of PanK through X-ray crystallography, a crystal of
PanK is required. Based on the results from the thermal shift assay and DLS experiment, the gel
filtration buffer chosen to be used for PanK was 100 mM sodium citrate with a pH 6.0 containing
250 mM NaCl, 1 mM TCEP and 5% glycerol. All crystallization screens that were used had 96
conditions each, meaning a total number of 384 conditions were tested for the crystallization of
PanK. Crystals of PanK can be observed in all crystallization screens. However, Ligand friendly
crystallization kit and Pact premier™crystallization kit appeared to be the best among the kits
that were used as PanK crystallized in many conditions provided by these kits. The crystal mor-
phology was always in the form of thin needles as exemplified by PanK crystals in 0.1 M MES
buffer containing 0.2 M magnesium chloride hexahydrate and 25 % (w/v) PEG 6000 at 20◦C
(Figure 3.6).
Crystals were illuminated with UV radiation after 5 and 21 days for detection of protein
crystals. UV fluorescence from the crystals was detected (Figure 3.7) which confirmed that the
crystals in the drop was indeed protein crystals and not salt or buffer crystals. Crystals of His-tag
PanK could be observed in the condition containing 0.1MMMT pH 6 and 30 % (w/v) PEG 1000
(Ligand friendly) at 20◦C. Crystals of His-tag PanK grown at 8◦C could be observed in three
conditions that shared the same chemicals namely 0.1 M Bis Tris Propane, 0.2 M sodium iodide,
20 % (w/v) PEG 3350 and 10 % (v/v) ethylene glycol (Ligand friendly). The only difference be-
tween these condtions was the pH. Unlike the crystals of PanK, the morphology of the His-tag
PanK crystals appeared as small broken plates. Crystals of PanK grown in the conditions 2.2 M
ammonium sulfate containing 0.2 MNaCl (AmSO4), 0.1 M Bis-Tris propane with a pH 6.5 con-
taining 0.2 M sodium nitrate and 20 % (w/v) polyethylene glycol (PEG) 3350 (Ligand friendly),
0.1 M Bis-Tris propane with a pH 6.5 containing 0.2 M sodium formate and 20 % (w/v) PEG
3350 (Ligand friendly) were tested for diffraction. In addition, His-tag PanK crystallized 0.1 M
MMT pH 6 and 30 % (w/v) PEG 1000 was also tested for diffraction. None of the crystals were
able to diffract.
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Figure 3.6: Crystals of PanK grown in the condition that contained 0.1MMES pH 6.0, 0.2Mmagnesium
chloride hexahydrate and 20 % PEG 6000. The grown protein crystals could be observed after a week
growing in 20◦C .
Figure 3.7: UV-picture of the same protein crystals (Figure 3.6). By illuminating the protein crystals
with UV radiation, fluorescence can be detected from the protein crystals.
3.6 Virtual screening
In order to retrieved compounds relevant for the docking, compounds were first prepared by
calculating unique smiles for all compounds, stereosisomers and physico-chemical properties.
Libraries were then generated using the filters described in the section "Database for virtual
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screening". Among the 162888 compounds in the carboxylate group and 1977327 compounds
in the diverse group, 536 and 1281 compounds were able to dock into the biding site respectively.
The list of docked compounds were filtered by generating pharmacophore hypotheses based
on the bindings between the compounds and PanK. For the compounds containing carboxylate
group, a pharmacophore hypothesis was generated by featuring one negative ionic group based
on the carboxylate group on the compounds, one positive ionic group based on the charge group
on the compounds and one hydrogen bond donor that points towards Asp 101. Visual inspec-
tion of the compounds in the carboxylate group has shown that many of them tend to bind to
Asp 101 through the positive charged group in the form of hydrogen bonds and salt bridge. In
addition, the oxygens on the carboxylate group also tend to form interact with other residues in
the binding site. Therefore, the compounds in the carboxylate group were screened using the
pharmacophore hypothesis described earlier. Compounds were screened by keeping their posi-
tions rigid. After screening, 344 compounds were accepted by the pharmacophore hypothesis
and inspected by eye. Among the 344 compounds, 14 of themwere considered for hit validation.
For the diverse group, two pharmacophore hypotheses were generated. The first pharma-
cophore hypothesis contained the same features as the one used for the carboxylate group except
the negative ionic group is replaced by a hydrogen bond acceptor. Visual inspection of the com-
pounds in the diverse group showed that many of them also tend to bind to Asp 101 through the
positive charged group which was the reason why the hydrogen bond donor and positive ionic
group were kept intact. As for the replacement of the negative ionic group with a hydrogen bond
acceptor was to cover all funtional groups that could act as a hydrogen bond acceptor. Among
the 1281 compounds that were screened, 38 of them were accepted by the pharmacophore hy-
pothesis and inspected by eye. The second pharmacophore was generated in order to see the
importance the carboxylate group had for the binding. This pharmacophore replaced the hy-
drogen acceptor feature with an excluded carboxylate group. Among the 1281 compounds that
were screened, 3 of them were accepted by the pharamcophore and all of them existed in the 38
compounds that were screened with the first pharmacophore. A total amount of 6 compounds
from the diverse group were considered for hit validation.
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Table 3.18: Structures of compounds and predicted binding mode
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Table 3.19: Structures of compounds and predicted binding mode










56 CHAPTER 3. RESULTS
Chapter 4
Discussion
4.1 Overexpression of PanK
The goal in this experiment is to find suitable cell lines that can express PanK. E. coliC41 (DE3),
C43 (DE3), BL21 (DE3) and Rosetta (DE3) appeared to be suitable cell lines for the expression
of PanK. E. coli C41 (DE3) and C43 (DE3) were chosen for the expression of PanK. Both cell
lines were to be able to express His-tag PanK with a yield 7.9 mg/l cell culture. E. coli BL21
(DE3) and Rosetta (DE3) were not used for further expression. An interesting experiment that
could be conducted is to purify His-tag PanK from these two cell lines and compare the yield
between all four cell lines in order to see which cell line expresses most protein.
4.2 Purification of PanK
As mentioned in the result section, the goal of the of the purification experiment is to establish
a puification protocol for PanK. In each purification step, SDS-gel electrophoresis was used to
confirm the purity of the fractions. Each column from the flowthrough (lane. 3, 4, 5, and 6 Fig-
ure 3.2 A) indicated that some PanK did not bind to the nickel resin in the column. The reason
could be because the nickel resin was saturated so that no more PanK could bind to it anymore.
Another possible explanation is that these proteins were not PanK but protein with the sameMW.
TEV-protease has a MW of 27.45 kD and from sample nr. 2 on the SDS-PAGE (Figure 3.2
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B) it can be observed that the TEV-protease used for cleaving was not completely pure since
there were other undesired protein in the TEV-protease sample. The reason why the loading
sample was loaded into the gel (lane 3 Figure 3.2 B) is to compare it to the His-tag PanK (lane
4 Figure 3.2 B) since the loading sample is supposed to have a lower MW than the his-tagged
PanK but due to column 4 being overloaded, this comparison was not possible. This comparison
would have been possible if the samples were diluted before the SDS-PAGE gel electrophoresis.
SDS-PAGE (Figure 3.3 A) from the size exclusion chromatography suggested that the PanK
samples does not contain any other undesired proteins indicating a successful purification. As
mentioned in the previous section, phosphate buffer appeared to be a better at stabilizing PanK
than Tris-HCl. A His-tag affinity chromatography using phosphate buffer as lysis and elution
buffer was conducted hoping that aggregation can be reduced during purifications. The purified
His-tag PanK resulted in a very pure protein sample and no other undesired protein could be
observed on lane 9 (Figure 3.3 B). The only main differences between these two His-tag affinity
purification were that change of pH from 7.9 to 6.5 and 100 mM sodium phosphate was used in-
stead of 20 mM Tris-HCl. The reason for the improvement of the purity could be because of the
phsophate buffer and/or the change in pH but to be certain, the purification should be repeated.
4.3 Dynamic light scattering and thermal shift assay
A previously published protocol was used as guideline [9], therefore, Tris-HCl was initially cho-
sen as the buffer for purification and gel-filtration of the PanK. However, PanK has shown that
it may aggregates in this buffer (Figure 3.4). To find a more suitable buffer for crystallization
a uffer screnn was conducted. In order to cover a wide range of conditions, it was decided to
use the Rubic buffer screen kit followed by Rubic additive screen kit. From the results of the
buffer screen, the best buffer for PanK appeared to be phosphate buffer and citric acid buffer
at a pH around 6 and 6.5 (Table 3.1 and 3.3). However, phosphate buffer is not suitable when
crystallizing protein since phosphate tend to form salt crystals. For that reason, it was decided
to use citric acid buffer for the additive screen. In addition, Tris-HCl buffer was also used as this
buffer was used previously for the protein purification [9]. Another buffer that could be inter-
esting to use as gel-filtration buffer for PanK is 100 mM ammonium acetate pH 7.3. The result
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of this buffer from the buffer screen (Table 3.1) indicates that this buffer is also suitable for PanK.
As mentioned in the results section, protein should not form aggregates when it is used for
crystallization. Therefore, DLS experiment was conducted in order to find potential PanK aggre-
gates. Both the intensity curve and correlogram obtained from Tris-HCl (Figure 3.4) suggested
that aggregates were present in the PanK solution as the results suggested that the solution was
very polydisperse. Results from the thermal shift assay suggested that citrate is a better buffer
for PanK crystallization (Table 3.1), thus, a DLS experiment was conducted using citrate as
buffer.The intensity curve obtained with PanK purified with the citrate buffer for gel filtration
(Figure 3.5 A) still showed multiple peaks at different sizes. However, the correlogram (Fig-
ure 3.5 B) from citrate appeared to had improved compared to the correlogram from Tris-HCl
(Figure 3.4 B). The different peaks shown on the intensity curve (Figure 3.5 A) does not need
to be protein aggregates, these peaks could possibly be the different additives that were added
to the buffer (250 mM NaCl, 1 mM TCEP, 5% glycerol) since there was no option to instruct
the instrument to ignore the additives. Overall, the results obtained from the buffer screen sug-
gested that citrate and phosphate are more suitabe buffers for PanK than Tris-HCl while results
from the DLS experiment also appeared to support the statement that citrate was a more suitable
buffer for PanK.
4.4 PanK crystallization
Due to the results achived from the thermal shift assay experiemnt, it was decided to redesign
the gel filtration buffer from Tris-HCl to citrate. The new buffer contained 100 mM sodium cit-
rate pH 6.0, 250 mM NaCl, 1 mM TCEP and 5 % glycerol. For His-tag purification a phosphate
buffer was used in hopes of getting a better yield of PanK and having it more stabilize. The
purification resulted in very pure His-tag PanK, therefore, it was decided to attempt to crystal-
lize His-tag PanK as well. Protein crystallization is a trial and error experiment, thus, it was
attempted to crystallize PanK in a wide range of crystallization screen and in different tempera-
tures to observe if PanK crystallizes in the different conditions that were used. PanK managed
to crystallize in all crystallization screens in form of thin needles. The challenge of having pro-
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tein crystals in this morphology is that taking them out from the plate without breaking them is
very diffucult. As mentioned in the result section, Ligand friendly crystallization kit and Pact
premier™crystallization kit appeared to be the best among the kits for crystallization of PanK.
For the crystallization using Ligand friendly kit, PanK usually crystallized in conditions with a
pH from 6 to 8 containing sodium salt, and PEG and ethylene glycol as precipitants. The condi-
tions where PanK crystallized using Pact premier™kit shared a strong resemblances with Ligand
friendly kit except ethylene glycol was not used in Pact premier™crystallization kit. This could
indicate that PanK prefer to crystallize in these conditions and could serve as a starting point for
future crystallization attempt. As for the other crystallization kits that were used, PanK crystal-
lized in a very few conditions. Again, PanK crystals was observed in conditions that contained
sodium salts and the precipitant PEG which further indicates that these chemicals are important
for the crystallization. Crystals were not able to diffract, thus, data could not be collected from
them.
4.5 Virtual screening
A library of 89305 carboxylates and a library of 975408 diverse small molecules were screened
for PanK inhibitors. In total, 1817 compounds were suggested for testing. All selected com-
pounds were predicted to have a LLE of ++ by the Hyde scoring function. In addition, it was
required that the compounds form an interaction with Asp 101 as seen for pantothenate. Among
the 20 compounds that were selected, 14 of them are from the carboxylate group (Table ??, com-
pound id 1-11 and Table 3.19, compound id 12-14) while the rest is from the diverse group(Table
3.19, compound id 15-20).
As mentioned in the results section, pharmacophore hypotheses were generated for both
groups in order to filter the docked compounds. The pharmacophore for the carboxylate group
contained a negative ionic group, one positive ionic group and one hydrogen bond donor that
points Asp101. These features were selected because inspection of compounds revealed that the
compounds mainly formed interactions with PanK through the charged group and carboxylate
group. Compounds were selected based on the bindings they form with PanK. As examplified
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by compound nr. 2 (Figure 4.1), compounds that formed hydrogen bonds with both oxygens
on Asp 101 and both oxygens on the carboxylate group interacted with other residues were pre-
ferred.
Two pharmacophore hypotheses were generated for the diverse group. The first pharma-
cophore contained the feature types positive ionic group, a hydrogen bond donor and a hydro-
gen bond acceptor. The second one replaced the acceptor with an excluded carboxylate group.
Among the 1281 compounds that were screened with the first pharmacophore hypothesis, 38
compounds were accepted by the pharmacophore. Out the 1281 compounds that were screened
with the second pharmacophore, only 3 compounds were accepted. Compounds that contained a
carboxylate group could still be found after screening with the first pharmacophore. This might
indicate that carboxylate group is important for the binding to PanK and this idea was supported
by the screening with the second pharmacophore. All selected compounds in this group (Table
3.19, compound id 15-20) interacted with Asp 101 using hydrogen bonds and salt bridges and
two of them had a carboxylate group attached (Table 3.19. compound id 15 and 20). Overall, the
docking of the two libraries has provided some compounds that could serve as starting point for
discovering new inhibitor for PanK. In order to validate the hits, the compounds must be tested
experimentally to confirm if they are actually active against PanK.
Figure 4.1: Binding mode examplified by compound nr. 2. In this example, the charged group is forming
salt bridge (green dotted lines) and hydrogen bond (pink dotted lines) with Asp 101. Additional inter-
actions are also formed via the carboxylate group by interacting with Arg 102, Thr 180, Gly 99 and Tyr
92.
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Chapter 5
Conclusion and future perspective
In this thesis type 3 Pank from P. aeruginosa was chosen as target for the discovery of new
starting for developing new antibiotics. A purification protocol for the protein was established.
A series of thermal shift assay showed that phosphate buffer at pH 6.0 appeared to be the best
buffer for the protein. Purification attempt of the protein with this buffer for His-tag affinity chro-
matography resulted in very pure his-tag PanK. Further purification attempts using this buffer
should be pursued in order to see if the results can be replicated and if the yield of protein is
improved. Virtual screening identified compounds that theoretically bind to the pantothenate
binding site of PanK. Based on the interactions with Asp 101, 20 compounds were chosen. In
future experiments, binding assays using the identified compounds should be developed using
for example BioLayer Interferometry (BLI) which allows screening the compounds with PanK
and determining the binding constants of the screening hits. PanK was able to form crystals in
form of needles. Unfortunately, did not diffract and no data could be collected from the them.
A new crystallization approach should be conducted.
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